The survey findings, published in the Journal of Managed Care & Specialty Pharmacy, showed 62% of respondents predict that the number of active drug shortages will rise by more than 25% within five years, potentially worsening patient access to critical medications.
In addition, 92% of respondents reported they anticipate AI will be more integrated into more than half of prior authorization reviews.
Another pressing concern for participants was the rise in drug costs, with 54% expecting at least half of U.S. states to establish drug-affordability boards. Additionally, 97% foresee a 25% surge in GLP-1 therapies.
The foundation is the philanthropic arm of the AMCP.